Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-02-09
2010-10-26
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S364000, C514S254060
Reexamination Certificate
active
07820821
ABSTRACT:
The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
REFERENCES:
patent: 4925853 (1990-05-01), Smith et al.
patent: 6017919 (2000-01-01), Inaba et al.
patent: 6114532 (2000-09-01), Ries et al.
patent: 6303600 (2001-10-01), Cox et al.
patent: 6316474 (2001-11-01), McCauley et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 6605632 (2003-08-01), Lesieur et al.
patent: 6872851 (2005-03-01), Lesieur et al.
patent: 6878712 (2005-04-01), Butlin et al.
patent: 6951948 (2005-10-01), Deng et al.
patent: 2002/0107245 (2002-08-01), Wagle et al.
patent: 2002/0156073 (2002-10-01), Wagle et al.
patent: 2003/0109714 (2003-06-01), Wishart et al.
patent: 2003/0171411 (2003-09-01), Kodra et al.
patent: 2004/0002424 (2004-01-01), Minn et al.
patent: 2004/0127492 (2004-07-01), Vazquez et al.
patent: 2004/0186148 (2004-09-01), Shankar et al.
patent: 2004/0229864 (2004-11-01), Bourrain et al.
patent: 2005/0101600 (2005-05-01), Seko et al.
patent: 2005/0176760 (2005-08-01), Cezanne et al.
patent: 2006/0019967 (2006-01-01), Wu et al.
patent: 2006/0068998 (2006-03-01), Negoro et al.
patent: 2006/0148855 (2006-07-01), Macdonald et al.
patent: 0 260 744 (1988-03-01), None
patent: 0 266 326 (1988-05-01), None
patent: 0 385 850 (1990-09-01), None
patent: 1 375 486 (2004-01-01), None
patent: WO 96-39390 (1996-12-01), None
patent: WO 97-03069 (1997-01-01), None
patent: WO 97-11075 (1997-03-01), None
patent: WO 98-02438 (1998-01-01), None
patent: WO 02-39987 (2002-05-01), None
patent: WO 03-007955 (2003-01-01), None
patent: WO 03-053939 (2003-07-01), None
patent: WO 03-082272 (2003-10-01), None
patent: WO 2004-063169 (2004-07-01), None
patent: WO 2004-085425 (2004-10-01), None
patent: WO 2004-087153 (2004-10-01), None
patent: WO 2005-016914 (2005-02-01), None
patent: WO 2005-032548 (2005-04-01), None
patent: WO 2005-035526 (2005-04-01), None
patent: WO 2005-042520 (2005-05-01), None
patent: WO 2005-090379 (2005-09-01), None
patent: WO 2006-086539 (2006-08-01), None
patent: WO 2006-099379 (2006-09-01), None
Patent Cooperation Treaty, International Preliminary Report on Patentability, International Appl. No. PCT/US2007/003579, Int'l Filing Date Sep. 2, 2007, Mailed Aug. 21, 2008.
Office Action in U.S. Appl. No. 11/374,723 of Mar. 21, 2008.
Prosecution history of U.S. Appl. No. 11/374,723, as of Mar. 11, 2009.
Cockerill et al., “Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erB-2” Bioorganic & Medicinal Chemistry Letters, vol. 11, pp. 1401-1405 (2001).
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Schwink et al.: “Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.” XP002439665 retrieved from STN Database accession No. 2004:696342 abstract & WO 2004-072025, Aug. 26, 2004.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Inoue et al: “Preparation of isoquinoline and isochroman derivatives for treating virus infectious diseases.” XP002439666 retrieved from STN Database accession No. 2003: 796470 abstract & WO 2003-082265; Oct. 9, 2003.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Fuji et al: “Preparation of nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity.” XP002439667 retrieved from STN Database accession No. 2002:695955 abstract & WO 2002-070486; Sep. 12, 2002.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Kubo et al: “Benzimidazole derivatives as neovascularization Inhibitors and pharmaceutical compositions containing them.” XP002439668 retrieved from STN Database accession No. 2000:356164 abstract & JP 2000 143635; May 26, 2000.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Das et al: “Preparation of cyclic protein tyrosine kinase inhibitors.” XP002447592 retrieved from STN Database accession No. 2000:756524, RN: 302963-85-5 abstract & WO 2000-62778; Oct. 26, 2000.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Garin et al: “Diheterocyclic compounds from dithiocarbamates and derivatives thereof. II. 2, 2′—Diamino-6, 6′-bibenzoazoles.” XP002447593 retrieved from STN Database accession No. 1990:440541, RN: 127933-27-1; 127933-2; 127933-29-3; 127933-30-6; 127933-38-4; 127933-39-5; 127933-40-8; 127933-41-9 abstract & Journal of Heterocyclic Chemistry, 27(2); 1990.
Database Caplus Online, Chemical Abstracts Service, Columbus, Ohio, US; Yamamoto et al: “2-p-(Substituted amino) anilinobenzimidazoles.” XP002447594 retrieved from STN Database accession No. 1980:111007 RN: 72838-56-3; 72838-64-3 abstract & JP 54081271; Jun. 28, 1979.
International Search Report for related PCT application PCT/US2007/003579, mailed Apr. 9, 2007.
Written Opinion for related PCT application PCT/US2007/003579, mailed Apr. 9, 2007.
Office Action from U.S. Appl. No. 11/374,723 mailed Sep. 2, 2008.
Claims in U.S. Appl. No. 11/374,723 as of Jun. 19, 2009.
Adams, et al., “Chromosomal passengers and the (aurora) ABCs of mitosis,” Trends in Cell Biology, vol. 11, No. 2, pp. 49-54(6) (2001). (abstract only).
Bischoff, et al., “The Aurora/Ipl1p kinase family; regulators of chromosome segregation and cytokinesis,” Trends in Cell Biology, vol. 9, No. 11, pp. 454-459, (1999). (abstract only).
Chieffi, et al. “Aurora B Expression Directly Correlates with Prostate Cancer Malignancy and Influence Prostate Cell Proliferation,” Prostate, vol. 66(3), pp. 326-333 (2006).
Knighton, et al., “Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase,” Science, vol. 253, No. 5018, pp. 407-414 (1991). (abstract only).
Kuang et al., “Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation,” Nat Genet., vol. 20(2), pp. 189-193 (1998). (abstract only).
The Protein Kinase Facts Book I, Academic Press, San Diego, Calif., 1995. (Table of Contents and Title Page).
The Protein Kinase Facts Book II, Academic Press, San Diego, Calif., 1995. (Table of Contents and Title Page).
Zhou, et al., “Tumour amplified kinaseSTK15/BTAKinduces centrosome amplification, aneuploidy and transformation,” Nature Genetics, vol. 20, pp. 189-193 (1998). (abstract only).
Examiner's Report from corresponding European Patent Office (EP Office) Application No. 07 750 418.1 issued on Dec. 1, 2008.
Bischoff et al., The EMBO J. 17(11) 3052-3065 (1998).
Hanks et al., T. FASEB J. 9, 576-596, (1995).
Hiles et al., Cell 70, 419-429 (1992).
Kimura et al., J. Biol. Chem. 274(11), 7334-7340, (1999).
Miyoshi et al., Int. J. Cancer 92, 370-373, (2001).
Sakakura et al., British Journal of Cancer 84(6), 824-831, (2001).
Takahashi et al., Japan J. Cancer Res. 91, 1007-1014, (2000).
Tatsuka et al., Cancer Research 58, 4811-4816, (1998).
Hu et al., Oncol. Res. 15(1), 49-57, (2005).(abstract only).
Andrews Robert C.
Arimilli Murty N.
Davis Stephen
Gopalaswamy Ramesh
Grella Brian S.
Kilpatrick & Stockton LLP
Stockton Laura L.
TransTech Pharma, Inc.
LandOfFree
Benzazole derivatives, compositions, and methods of use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzazole derivatives, compositions, and methods of use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzazole derivatives, compositions, and methods of use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157251